Pain Therapeutics, Inc. (PTIE) Reaches $9.87 After 6.00% Down Move; Pfizer (PFE) Shorts Decreased By 31.19%

May 21, 2018 - By Marie Mckinney

Pfizer Inc. (NYSE:PFE) Logo

The stock of Pain Therapeutics, Inc. (NASDAQ:PTIE) is a huge mover today! The stock decreased 3.33% or $0.34 during the last trading session, reaching $9.87. About 65,988 shares traded. Pain Therapeutics, Inc. (NASDAQ:PTIE) has risen 11.52% since May 21, 2017 and is uptrending. It has underperformed by 0.03% the S&P500.The move comes after 5 months negative chart setup for the $68.06M company. It was reported on May, 21 by Barchart.com. We have $9.28 PT which if reached, will make NASDAQ:PTIE worth $4.08 million less.

Pfizer Inc (NYSE:PFE) had a decrease of 31.19% in short interest. PFE’s SI was 98.32 million shares in May as released by FINRA. Its down 31.19% from 142.88M shares previously. With 23.71 million avg volume, 4 days are for Pfizer Inc (NYSE:PFE)’s short sellers to cover PFE’s short positions. The stock increased 0.25% or $0.09 during the last trading session, reaching $35.73. About 10.38 million shares traded. Pfizer Inc. (NYSE:PFE) has risen 2.43% since May 21, 2017 and is uptrending. It has underperformed by 9.12% the S&P500.

Pain Therapeutics, Inc., a biopharmaceutical company, develops drugs for treating nervous system in the United States. The company has market cap of $68.06 million. The companyÂ’s lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief. It currently has negative earnings. It also develops FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; and PTI-125, a small molecule drug candidate to treat AlzheimerÂ’s disease and other neurological disorders.

More important recent Pain Therapeutics, Inc. (NASDAQ:PTIE) news were published by: Seekingalpha.com which released: “FDA OKs first non-opioid treatment for opioid withdrawal” on May 16, 2018, also Benzinga.com published article titled: “Why Knowing Your Goals Will Make You A Better Trader, Investor and Saver”, Benzinga.com published: “41 Biggest Movers From Yesterday” on May 17, 2018. More interesting news about Pain Therapeutics, Inc. (NASDAQ:PTIE) was released by: Nasdaq.com and their article: “Pain Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update on REMOXY® ER” with publication date: May 09, 2018.

Among 22 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 12 Hold. Therefore 41% are positive. Pfizer had 79 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Friday, August 28 by Piper Jaffray. The stock of Pfizer Inc. (NYSE:PFE) has “Neutral” rating given on Wednesday, January 31 by Credit Suisse. The rating was maintained by Leerink Swann with “Market Perform” on Monday, May 2. The stock of Pfizer Inc. (NYSE:PFE) has “Overweight” rating given on Wednesday, September 20 by Morgan Stanley. The stock has “Hold” rating by Societe Generale on Wednesday, April 6. On Wednesday, November 25 the stock rating was upgraded by SunTrust to “Neutral”. The rating was upgraded by Barclays Capital on Tuesday, November 29 to “Overweight”. SunTrust maintained Pfizer Inc. (NYSE:PFE) on Sunday, January 28 with “Hold” rating. BMO Capital Markets maintained Pfizer Inc. (NYSE:PFE) rating on Tuesday, September 5. BMO Capital Markets has “Buy” rating and $37.0 target. The stock has “Hold” rating by S&P Research on Wednesday, October 28.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $209.01 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 9.93 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Investors sentiment increased to 1.06 in 2017 Q4. Its up 0.10, from 0.96 in 2017Q3. It increased, as 51 investors sold Pfizer Inc. shares while 675 reduced holdings. 134 funds opened positions while 632 raised stakes. 4.07 billion shares or 0.28% more from 4.06 billion shares in 2017Q3 were reported. Inverness Counsel Lc Ny invested 0.09% in Pfizer Inc. (NYSE:PFE). Hl Service Limited Liability reported 2.21% stake. Old Second State Bank Of Aurora holds 115,375 shares or 1.65% of its portfolio. Riverhead Management has 380,690 shares for 0.58% of their portfolio. Tcw Group Inc owns 162,469 shares or 0.05% of their US portfolio. Boston Common Asset Mgmt Limited Liability Company holds 0.04% in Pfizer Inc. (NYSE:PFE) or 8,503 shares. Notis owns 15,000 shares or 0.31% of their US portfolio. Vident Advisory Ltd Liability stated it has 0.07% in Pfizer Inc. (NYSE:PFE). Annex Advisory Ltd Liability owns 39,400 shares for 0.27% of their portfolio. Legal And General Gru Public Ltd has invested 0.82% in Pfizer Inc. (NYSE:PFE). State Farm Mutual Automobile Insur Commerce reported 59.68M shares or 2.72% of all its holdings. Bankshares Of Montreal Can, Ontario – Canada-based fund reported 17.59 million shares. Alpha Windward Ltd Liability reported 8,985 shares stake. Natl Bank Of Nova Scotia Trust holds 0.15% of its portfolio in Pfizer Inc. (NYSE:PFE) for 38,645 shares. American Registered Inv Advisor reported 60,776 shares.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “ViiV Healthcare’s HIV med Juluca OK’d in Europe” on May 21, 2018, also Fool.com with their article: “Better Buy: Pfizer Inc. (PFE) vs. Merck (MRK)” published on May 13, 2018, 247Wallst.com published: “How Much Pfizer Earnings Depend on a Few Brands” on May 01, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: 247Wallst.com and their article: “What to Look For in the Merck and Pfizer Reports Tuesday Morning” published on April 30, 2018 as well as Seekingalpha.com‘s news article titled: “Pfizer: Buy This Dip?” with publication date: May 03, 2018.

Since December 15, 2017, it had 0 buys, and 13 sales for $17.75 million activity. On Saturday, February 24 LUND-JURGENSEN KIRSTEN sold $353,677 worth of Pfizer Inc. (NYSE:PFE) or 9,510 shares. $986,292 worth of Pfizer Inc. (NYSE:PFE) shares were sold by HILL CHARLES H. 1,758 shares valued at $64,679 were sold by CORNWELL W DON on Monday, February 26. The insider JOHNSON RADY A sold 27,323 shares worth $998,666. LANKLER DOUGLAS M had sold 50,000 shares worth $1.84 million. Dolsten Mikael also sold $501,398 worth of Pfizer Inc. (NYSE:PFE) shares. Another trade for 6,750 shares valued at $249,750 was sold by MACKENZIE ALEXANDER R.

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>